There is a clear recognition of the relationship between thrombosis and neoplastic diseases. In recent years, there have been a few reports dealing with some of the features of clinical progression and management of venous thromboembolism (VTE) in palliative care patients. In this report, we present four cases that describe some of the diverse aspects of this clinically challenging area to illustrate the symptom and quality of life issues for patients, and the management challenge for palliative care clinicians. Perhaps the most important issue in the palliative care setting is the need to balance the inconvenience of the various diagnostic and therapeutic options, particularly in settings where progression has resulted in a deteriorated physical and cognitive condition. We need to recognize that VTE does cause significant problems for some of our patients. We will always need to balance issues of life expectancy, comfort and quality of life, and risk and benefits of anticoagulation, and align these problems with the individual patient, and the family dynamics and desires we encounter.
Get full access to this article
View all access options for this article.
References
1.
Walsh-McMonagleD., GreenD.Low molecular weight heparin in the management of Trousseau's syndrome. Cancer1997; 80(4): 649–655.
2.
HirshJ., LeeA.Y.Y.How we diagnose and treat deep vein thrombosis. Blood2002; 99(9): 3102–3110.
3.
SarasinF., EckmanM.Management and prevention of thromboembolic events in patients with cancer related hypercoagulable states. J Gen Intern Med1993; 9: 476–486.
4.
JohnsonM.J., SherryK.How do palliative physicians manage thromboembolism?Palliat Med1997; 11(6): 462–468.
5.
VonDepka ProndzinskiM., KarthausM., GanserA., BarthelsM.Anticoagulant prophylaxis and therapy in patients with cancer. Antibiot Chemother2000; 50: 149–158.
6.
ChanA., WoodruffR.K.Complications and failure of anticoagulation therapy in the treatment of venous thromboembolism in patients with disseminated malignancy. Aust N Z J Med1992; 22: 119–122.
7.
JohnsonM.J.Problems of anticoagulation within a palliative care setting: an audit of hospice patients taking warfarin. Palliat Med1997; 11(4): 306–312.
8.
DouketisJ., FosterG., CrowtherA., PrinsM., GinsbergS.Clinical risk factors and timing of recurrent venous thromboembolism during the initial three months of anticoagulant therapy. Arch Intern Med2000; 160: 3431–3436.
9.
MerminodT., ZulianG.B.Diagnosis of venous thromboembolism in cancer patients receiving palliative care. J Pain Symptom Manage2000; 19(4): 238–239.
10.
MeyerG., MarijanovichZ., ValckeJ., LorcerieB., GruelY., Solal-CelignyP.Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch Intern Med2002; 162: 1729–1735.
11.
JohnsonM.G., SprouleM.W., PaulJ.The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Clin Oncol1999; 11: 105–110.
12.
HuttenB.A., PrinsM.H., GentM., GinsbergJ., TijssenJ.G., BullerH.R.Incidence of recurrent and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved INR—a retrospective analysis. J Clin Oncol2000; 18: 3078–3083.
13.
KakkarA., WilliamsonR.Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost1999; 25(2): 239–243.
14.
RassmussenM.Preventing thromboembolic complications in cancer patients after surgery—a role for prolonged thromboprophylaxis. Cancer Treat Rev2002; 28: 141–144.
LevineM., HirshJ., GentM., ArnoldA., WarrD., FalangaA.Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet1994; 343: 886–889.
17.
MoussaS.The low-molecular-weight heparin tinzaparin in thrombosis and beyond. Cardiovasc Drug Rev2002; 20(3): 163–180.
18.
ArkelY.S.Thrombosis and cancer. Semin Oncol2000; 27(3): 362–374.
19.
JohnsonM.J.Bleeding, clotting and cancer. Clin Oncol1997; 9: 294–301.
20.
GodwinJ.Use of low-molecular-weight heparin in malignancy. Thromb Haemost1996; 2: S28–S34.
21.
EllisS.N., BoggsH.W., SlagleG.W., ColeP.A., CoyleD.J., BlakemoreW.S.Protein C activity, stage of disease, and vascular thrombosis in colon carcinoma. Am J Surg1992; 163: 78–81.
22.
ten WoldeM., KraaijenhagenR.A., PrinsM.H., BullerH.R.The clinical usefulness of D-dimer testing in cancer patients with suspected deep venous thrombosis. Arch Intern Med2002; 162: 1880–1884.
23.
WeinmannE.E., SalzmanE.W.Deep-vein thrombosis. N Engl J Med1994; 331: 1630–1641.
24.
JohnsonM.G., WalkerI.D., SprouleM.W., ConkieJ.Abnormal coagulation and deep venous thrombosis in patients with advanced cancer. Clin Lab Haematol1999; 21: 51–54.
25.
BonarD., HickeyA.D., WallaceD.M.Efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost1997; 8: 137–140.
26.
GitterM.J., JaegerT.M., PettersonT.M., GershB.J., SilversteinM.D.Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc1995; 70: 725–733.
LevineM.N.Managing thromboembolic diseases in the cancer patients: efficacy and safety of antithrombotic treatment options in patients with cancer. Cancer Treat Rev2002; 28: 145–149.
29.
SmonenburgS.M., HuttenB., PrinsM.Should patients with cancer be treated differently. Haemostasis1999; 29(1): 91–97.
30.
LukC., WellsP., AndersonD., KovacsM.Extended outpatient therapy with low molecular heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med2001; 111: 270–273.
31.
SchwarzR., MarreroA., Conlon, BurtM.Inferior vena cava filters in cancer patients—indications and outcome. J Clin Oncol1996; 14(2): 652–657.
32.
MarcyP.Y., MagneN., GallardJ.C., BondiauP.Y., FrenayM., DescampsB.Cost-benefit assessment of inferior vena cava filter placement in advanced cancer patients. Support Care Cancer2002; 10: 76–80.
